Crossmark

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)

Crossref DOI link: https://doi.org/10.1186/s12876-022-02411-w

Published Online: 2022-07-14

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Iimura, Yohei https://orcid.org/0000-0002-3473-8244
Furukawa, Naoki

Ishibashi, Masaaki

Ahiko, Yuka

Tanabe, Taro

Aikou, Susumu

Shida, Dai

Nojima, Masanori

Kuroda, Seiichiro

Boku, Narikazu
License Information

Text and Data Mining valid from 2022-07-14

Version of Record valid from 2022-07-14
More Information

Article History

Received: 3 May 2022

Accepted: 3 July 2022

First Online: 14 July 2022

Declarations

:

: This protocol was reviewed and approved by the certified Clinical Research Review Board of the University of Tokyo (approval number: 2021512SP) prior to conducting the trial. This clinical trial was conducted in compliance with the Clinical Trials Act in Japan and was registered in the Japan Registry of Clinical Trials (jRCT) as jRCTs031220002. All patients will be required to provide written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below